<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03381287</url>
  </required_header>
  <id_info>
    <org_study_id>HTD1801.PCT004</org_study_id>
    <nct_id>NCT03381287</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HighTide Biopharma Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HighTide Biopharma Pty Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicenter, multiple ascending dose
      (MAD) study to evaluate the safety and tolerability, PK, and PD profiles of HTD1801 in
      overweight to obese adults with hypercholesterolemia. There will be 3 cohorts of dose levels
      as 500, 1000 and 2000mg/day, 16 subjects for each cohort with 12 subjects will administer
      HTD1801 and 4 subjects will administer Placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 13, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency and severity of adverse events</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration of HTD1801 components (Cmax)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of Low-density lipoprotein-C (LDL-C)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>500mg HTD1801</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1000mg HTD1801</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2000mg HTD1801</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTD1801 Tablets, 500mg</intervention_name>
    <description>16 participants will be randomized 3:1 to receive 500mg of either HTD1801 or placebo, bid. The treatment duration will be 4 weeks.</description>
    <arm_group_label>500mg HTD1801</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTD1801 Tablets, 1000mg</intervention_name>
    <description>16 participants will be randomized 3:1 to receive 1000mg tablets of either HTD1801 or placebo, bid. The treatment duration will be 4 weeks.</description>
    <arm_group_label>1000mg HTD1801</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTD1801 Tablets, 2000mg</intervention_name>
    <description>16 participants will be randomized 3:1 to receive 2000mg of either HTD1801 or placebo, bid. The treatment duration will be 4 weeks.</description>
    <arm_group_label>2000mg HTD1801</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have given written informed consent

          2. Males or females aged 18 to 70 years old at the time of first dosing

          3. Have a body mass index (BMI) of &gt;25.0 and ≤ 45.0 kg/m2 at Screening

          4. Have a documented history of hypercholesterolemia, defined as LDL-C ≥ 2.59 mmol/L

        Exclusion Criteria:

          1. The use of any anti-dyslipidemia agent within 28 days prior to dosing

          2. History of a total cholesterol ≥ 10.35 mmol/L or triglyceride ≥ 11.3 mmol/L

          3. History of a clinically significant cardiac arrhythmia or clinically significant
             abnormal ECG results at Screening

          4. Significant peripheral or coronary vascular disease

          5. Clinically significant abnormal blood pressure at Screening or Baseline, defined as
             supine blood pressure ≥160/100 mmHg, or ≤ 90/60 mmHg

          6. Primary hypothyroidism (thyroid stimulating hormone [TSH] &gt; upper limit or normal
             [ULN] and free T4 &lt; lower limit of normal [LLN]), primary subclinical hypothyroidism
             (screening TSH &gt; ULN and free T4 within normal limits [WNL]), or secondary
             hypothyroidism (screening TSH &lt; LLN and free T4&lt; LLN) at Screening

          7. Glucose-6-phosphate dehydrogenase (G6PD) deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susan Gamble, Ph. D.</last_name>
    <phone>+1 301-801-8815</phone>
    <email>clinical.trials@hightidebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Q-Pharm Pty Ltd.</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Fung</last_name>
      <phone>+ 61 (0)738453657</phone>
      <email>m.fung@qpharm.com.au</email>
    </contact>
    <contact_backup>
      <last_name>Linda Dunn</last_name>
      <phone>+ 61 (0)738453629</phone>
      <email>l.dunn@qpharm.com.au</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Griffin, BSc, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CMAX Clinical Research Pty Ltd</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Mudge</last_name>
      <phone>+61 (0)870887949</phone>
      <email>katherine.mudge@cmax.com.au</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Ong</last_name>
      <phone>+61 (0)870887945</phone>
      <email>nicole.ong@cmax.com.au</email>
    </contact_backup>
    <investigator>
      <last_name>Nicholas Farinola, BSc, BMBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shashi Aggarwal</last_name>
      <phone>+61 (0)863825100</phone>
      <email>saggarwal@linear.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Hu</last_name>
      <phone>+61 (0)863825123</phone>
      <email>jhu@linear.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Gerald Watts, DSc, PhD, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

